Questex’s PODD, the Premier Gathering for Drug Delivery Industry Leaders, Announces the 16th Annual Conference Agenda

Questex's Fierce Life Sciences announced the agenda for the 16th annual PODD (Partnership Opportunities in Drug Delivery) Conference, scheduled for October 29-30, 2026, in Boston. The event will gather over 1,000 industry executives and features 150+ sessions with keynotes from Regeneron's Dr. George Yancopoulos and MIT's Dr. Robert Langer, covering topics including AI in drug delivery, pharma partnering strategies, and reimbursement challenges.

06/23/2026, 8:00 AM • GlobeNewswire

Should You Buy Moderna Before Aug. 5?

Moderna's investigational flu vaccine candidate (mRNA-1010) received unanimous FDA advisory panel approval, with a regulatory decision expected by August 5. The stock has surged over 100% this year as the company reaches a key transition point with multiple product launches planned for 2027-2028. However, the analyst suggests waiting for a post-approval dip to buy, as much of the good news may already be priced in.

06/22/2026, 6:10 PM • The Motley Fool

Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight

The cutaneous lupus erythematosus (CLE) market is projected to grow at 8% CAGR through 2036, driven by emerging targeted therapies and increased disease awareness. The market was valued at USD 650 million in 2025 across seven major markets. Key pipeline drugs from major pharmaceutical companies targeting plasmacytoid dendritic cells and type I interferon pathways are expected to transform treatment options for CLE patients.

06/22/2026, 1:00 PM • GlobeNewswire

Stock Market Today, June 18: Pfizer Falls as CFO Transition Tests Confidence in 2026 Outlook

Pfizer stock fell 2.74% following the announcement that CFO Dave Denton will depart in August, raising investor concerns about leadership continuity and the company's ability to meet 2026 guidance. While recent drug approvals strengthen the pipeline, the CFO transition creates uncertainty around financial execution and earnings recovery.

06/18/2026, 7:09 PM • The Motley Fool

3 Dividend Stocks to Hold for the Long Haul

The article recommends three healthcare dividend stocks for long-term investors: Bristol Myers Squibb, Merck, and Medtronic. Despite facing recent challenges like patent cliffs and competitive pressures, all three companies have strong dividend track records with consistent payout increases and promising pipelines to drive future growth.

06/16/2026, 6:15 AM • The Motley Fool

How Safe is Bristol Myers Squibb's Dividend? Here's My Honest Take.

Bristol Myers Squibb offers an attractive 4.5% dividend yield, well above market averages. While the company faces patent expirations on key drugs like Revlimid and Eliquis, its strong financial position, reasonable 72% payout ratio, investment-grade credit rating, and decades-long dividend history suggest the dividend is likely safe for most investors.

06/13/2026, 6:15 PM • The Motley Fool

Bristol Myers Squibb Dividend Raise Streak is 18 Years. Here's 1 Number That Says the Streak Will Continue.

Bristol Myers Squibb has maintained an 18-year dividend growth streak despite facing patent cliffs on flagship drugs like Eliquis. The company's $3.5 billion in planned cost savings by 2027 and a sustainable 40% payout ratio support continued dividend growth. With $10.5 billion in cash reserves, BMY appears well-positioned to maintain and grow its 4.5% dividend yield.

06/11/2026, 2:02 PM • The Motley Fool

Takeda AI-Drug Shows Superior Skin Clearance Against Bristol-Myers' Med

Takeda Pharmaceutical's AI-developed drug zasocitinib demonstrated statistical superiority over Bristol-Myers Squibb's deucravacitinib in a Phase 3 head-to-head trial for plaque psoriasis treatment. Zasocitinib achieved over 35% complete skin clearance (PASI 100) at week 16, more than 2.5 times the response rate of the competitor drug. The company plans to submit a New Drug Application to the FDA this fiscal year, with peak annual sales potential of $3-6 billion.

06/11/2026, 1:12 PM • Benzinga

Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery

Nxera Pharma has joined OpenFold, a non-profit AI research consortium for drug discovery, alongside major pharmaceutical and technology companies including Bristol Myers Squibb, Novo Nordisk, Bayer, Roche, AWS, Microsoft, and NVIDIA. The participation aligns with Nxera's strategy to enhance R&D productivity through AI technologies and leverage its NxWave™ GPCR drug discovery platform with open-source structural prediction models.

06/10/2026, 2:35 AM • GlobeNewswire

Better High-Yield Dividend Stock to Buy: Bristol Myers Squibb or Pfizer?

While Pfizer offers a higher dividend yield (6.7% vs 4.6%), Bristol Myers Squibb emerges as the better choice for income-focused investors due to superior dividend durability and growth. Bristol Myers has a healthier payout ratio (40% vs 60%), stronger average annual dividend growth (5.3% vs 4.4%), and greater sustainability potential despite facing similar near-term challenges as Pfizer.

06/04/2026, 2:30 AM • The Motley Fool

Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?

Recursion Pharmaceuticals and Schrödinger represent different approaches to AI-driven drug discovery—one biotech-focused with clinical-stage programs, the other software-first with recurring revenue. While both show strong growth (26.9% and 23.3% respectively), Recursion trades at a premium valuation (26.1x P/S) with significant losses and no approved products, while Schrödinger has a lower P/S ratio (4.3x) and improving profitability. The analyst recommends neither stock currently but would choose Schrödinger if forced to pick, citing its established software business and improving financial trajectory.

06/02/2026, 5:12 PM • The Motley Fool

Why Bristol Myers Squibb Stock Isn't Nearly As Cheap As It Looks

Bristol Myers Squibb appears attractively valued with a 16x P/E ratio and 4.4% dividend yield, but the discount is justified by significant patent expirations looming through 2028. Key drugs like Revlimid, Pomalyst, and Eliquis face generic competition, creating near-term headwinds. The stock may suit long-term investors but carries uncertainty in the short to medium term.

06/01/2026, 11:15 PM • The Motley Fool

CRISPR Therapeutics' Secret Weapon That Many Investors Are Overlooking

CRISPR Therapeutics acquired CTX611, a clinical-stage siRNA therapy targeting Factor XI for blood clot prevention, for $95 million upfront. The program could significantly impact the company's revenue despite being a follower in a competitive anticoagulant market dominated by Eliquis and other therapies. With only $1.4 million in Q1 2026 revenue, success with CTX611 could be transformative for the stock.

06/01/2026, 12:30 PM • The Motley Fool

CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?

The article compares two gene-editing biotech companies: CRISPR Therapeutics, which has FDA-approved CASGEVY therapy and stronger financials, versus Editas Medicine, which focuses on in vivo gene editing but lacks FDA approval and has a weaker balance sheet. CRISPR Therapeutics is recommended as the better 2026 investment due to its commercial-stage advantage, stronger cash position, and lower financial risk, despite Editas offering potentially greater upside if successful.

05/31/2026, 12:11 PM • The Motley Fool

Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

BioNTech and Bristol Myers Squibb announced interim Phase 2 data from the ROSETTA Lung-02 trial showing that their investigational bispecific immunomodulator pumitamig combined with chemotherapy demonstrated encouraging anti-tumor activity in first-line non-small cell lung cancer, with confirmed objective response rates of 63.6% in non-squamous and 72.7% in squamous subtypes at the lower dose. The drug showed consistent efficacy across PD-L1 expression levels with a manageable safety profile, and is advancing through a comprehensive Phase 3 development program.

05/30/2026, 2:15 PM • GlobeNewswire